343241-18-9Relevant articles and documents
Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1 H -indol-2-yl)-2- (trifluoromethyl)-4,7-dihydropyrazolo[1,5- a ]pyrimidin-6-yl)((S)-2-(3- methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I Kur inhibitor
Finlay, Heather J.,Lloyd, John,Vaccaro, Wayne,Kover, Alexander,Yan, Lin,Bhave, Gauri,Prol, Joseph,Huynh, Tram,Bhandaru, Rao,Caringal, Yolanda,Dimarco, John,Gan, Jinping,Harper, Tim,Huang, Christine,Conder, Mary Lee,Sun, Huabin,Levesque, Paul,Blanar, Michael,Atwal, Karnail,Wexler, Ruth
, p. 3036 - 3048 (2012/06/01)
Previously disclosed dihydropyrazolopyrimidines are potent and selective blockers of IKur current. A potential liability with this chemotype is the formation of a reactive metabolite which demonstrated covalent binding to protein in vitro. When substituted at the 2 or 3 position, this template yielded potent IKur inhibitors, with selectivity over hERG which did not form reactive metabolites. Subsequent optimization for potency and PK properties lead to the discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol- 2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S) -2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone (13j), with an acceptable PK profile in preclinical species and potent efficacy in the preclinical rabbit atrial effective refractory period (AERP) model.
